- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04316143
Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH
An Open-label, Multicentre Study to Evaluate Pharmacokinetics, Safety and Efficacy of Zamicastat as Adjunctive Therapy in Pulmonary Arterial Hypertension (PAH)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label, multi-centre study in patients with PAH who are currently on stable treatment with at least one PAH medication. It is planned to evaluate the PK profile (24 hour profile and trough levels) and the safety, tolerability and efficacy of four different zamicastat doses. Each patient will start treatment with the lowest dose (50 mg zamicastat once daily) and the dose will be up-titrated to the individual highest tolerated dose (HTD) i.e. up to 200 mg zamicastat once daily.
A data safety monitoring board (DSMB) will periodically review the safety data and will issue a recommendation if the doses can be used as planned.
This study will consist of:
- A screening period, 5 to 12 days: visit V1
Up to four dose finding periods, 14 days each:
- Dose A: visits A1, A2 and A3
- Dose B: visits B2 and B3
- Dose C: visits C2 and C3
- Dose D: visits D2 and D3
- Maintenance period, 42 days: visits MPV1, MPV2 and MPV3
- Follow-up period, 14 to 28 days: visits FU (down-titration) and FU
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28041
- Hospital Universitario "12 de Octubre"
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For inclusion in the study, patients must fulfil all of the following criteria:
- Male or female patients aged 18 to 65 years.
- Able to comprehend and willing to sign an informed consent form.
Diagnosis of PAH (pulmonary arterial hypertension WHO Group 1), documented by right heart catheterisation with a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg, a pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg and a pulmonary vascular resistance (PVR) > 3 WU [Galie N, et. al 2015; Lau EMT, et. al. 2017]:
- Idiopathic, in non-vasoreactive patients
- Heritable: Bone morphogenetic protein receptor type II (BMPR2) mutation and other mutations, in non-vasoreactive patients
- Drugs and toxin induced, in non-vasoreactive patients
- Associated with connective tissue disease
- Associated with simple congenital defects (atrial septal defect and/or ventricular septal defect) if closed > 12 months before inclusion.
- WHO functional class II or III as judged by the investigator.
- Stable treatment with at least one of the following approved PAH therapies for at least 90 days prior to V1: Ambrisentan, Bosentan, Macitentan, Riociguat, Selexipag, Sildenafil, Tadalafil, Epoprostenol intravenous, Iloprost inhaled or Treprostinil intravenous or subcutaneous.
Exclusion Criteria:
Patients having or being any of the following are to be excluded from the study:
- Contraindication to zamicastat, i.e. known hypersensitivity to ingredients of zamicastat formulation.
- Two or more consecutive measurements of SBP < 95 mmHg or DBP < 50 mmHg.
- Uncontrolled diabetes mellitus with HbA1c ≥ 8.5% within the last three months or at screening.
- PAH WHO Group 1 due to portal hypertension, human immunodeficiency virus (HIV) infection and schistosomiasis.
- Any disease known to cause pulmonary hypertension other than PAH WHO Group 1.
- Obstructive lung disease: Forced Expiratory Volume in 1 second/Forced Vital Capacity (FEV1/FVC) < 60% and FEV1 < 60% of predicted value after bronchodilator administration.
- Restrictive lung disease: Total Lung Capacity (TLC) < 70% of predicted value.
- History of moderate to severe hepatic impairment (Child-Pugh B and C).
- Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 (measured at V1).
- Use of the following prohibited medication or treatments during study participation: calcium channel blockers (CCBs) if used for the treatment of PAH in vasoreactive patients; drugs containing a catechol group that is metabolised by DβH e.g. rimiterole, isoprenaline, dopamine, dopexamine or dobutamide or α- and/or β-blockers.
- Current or previous (within the past year) alcohol or substance abuse excluding caffeine or nicotine.
- Presence of any other significant or progressive/unstable medical condition that, in the opinion of the investigator, would compromise evaluation of the study treatment or may jeopardise the patient's safety, compliance or adherence to protocol requirements.
For women: Pregnancy or breast-feeding. Women of childbearing potential unable or unwilling to undergo pregnancy tests and practice acceptable contraceptive measures from the time of informed consent until 30 days after last IMP intake. Acceptable methods for women are surgical intervention (e.g. bilateral tubal occlusion), non-hormonal implantable intrauterine device, double-barrier methods, true sexual abstinence (i.e. when this is in line with the preferred and usual lifestyle of the patient) and vasectomised partner (provided that the partner is the sole sexual partner of the patient and the partner has received medical assessment of the surgical success). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), hormonal contraceptives and withdrawal are not acceptable methods of contraception.
For men: Male patients who are sexually active with a partner of childbearing potential must use, with their partner, a condom plus an approved acceptable contraceptive measure from the time of informed consent until 90 days after the last IMP intake. The following methods are acceptable methods of contraception: partner's use of combined (oestrogen and progestogen-containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal); partner's use of progestogen-only hormonal contraception (oral, injectable/implantable, intrauterine hormone-releasing system); partner's use of implantable intrauterine device; surgical sterilisation (for example, vasectomy or bilateral tubal occlusion).
- Previous participation in any other drug investigational study within the past 30 days (or five half-lives of investigational medicinal product [IMP] whichever is longer) prior to V1.
- Vulnerable patients according to Section 1.61 of the ICH guideline for Good Clinical Practice E6.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 50 mg zamicastat
50 mg zamicastat once daily (half a tablet of 100 mg)
|
Tablets for oral administration under fed conditions containing 100 mg of zamicastat (BIA 5-1058)
Other Names:
|
Experimental: 100 mg zamicastat once daily
100 mg zamicastat once daily (one tablet of 100 mg)
|
Tablets for oral administration under fed conditions containing 100 mg of zamicastat (BIA 5-1058)
Other Names:
|
Experimental: 150 mg zamicastat once daily
150 mg zamicastat once daily (one and a half tablet of 100 mg)
|
Tablets for oral administration under fed conditions containing 100 mg of zamicastat (BIA 5-1058)
Other Names:
|
Experimental: 200 mg zamicastat once daily
200 mg zamicastat once daily (two tablets of 100 mg)
|
Tablets for oral administration under fed conditions containing 100 mg of zamicastat (BIA 5-1058)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the curve 0-24h (AUC0-24h) - 50 mg
Time Frame: Day 1 (0 hours and then 1, 2, 4, 8, 16 and 24 hours after IMP intake)
|
This PK parameters (24-hour profile) for zamicastat and its metabolites will be derived after a single dose of 50 mg zamicastat
|
Day 1 (0 hours and then 1, 2, 4, 8, 16 and 24 hours after IMP intake)
|
Area under the curve 0-24h (AUC0-24h) - HTD
Time Frame: 1, 2, 4, 8, 16 and 24 hours after IMP intake
|
This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD)
|
1, 2, 4, 8, 16 and 24 hours after IMP intake
|
Maximum plasma concentration (Cmax) - 50 mg
Time Frame: Day 1 (0 hours and then 1, 2, 4, 8, 16 and 24 hours after IMP intake)
|
This PK parameters (24-hour profile) for zamicastat and its metabolites will be derived after a single dose of 50 mg zamicastat
|
Day 1 (0 hours and then 1, 2, 4, 8, 16 and 24 hours after IMP intake)
|
Maximum plasma concentration (Cmax) - HTD
Time Frame: 1, 2, 4, 8, 16 and 24 hours after IMP intake
|
This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD)
|
1, 2, 4, 8, 16 and 24 hours after IMP intake
|
Time until Cmax (tmax) - 50 mg
Time Frame: Day 1 (0 hours and then 1, 2, 4, 8, 16 and 24 hours after IMP intake)
|
This PK parameters (24-hour profile) for zamicastat and its metabolites will be derived after a single dose of 50 mg zamicastat
|
Day 1 (0 hours and then 1, 2, 4, 8, 16 and 24 hours after IMP intake)
|
Time until Cmax (tmax) - HTD
Time Frame: 1, 2, 4, 8, 16 and 24 hours after IMP intake
|
This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD)
|
1, 2, 4, 8, 16 and 24 hours after IMP intake
|
Minimum plasma concentration at the end of the dosing interval (Cmin,SS) - HTD
Time Frame: 1, 2, 4, 8, 16 and 24 hours after IMP intake
|
This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD)
|
1, 2, 4, 8, 16 and 24 hours after IMP intake
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BIA-51058-201
- 2018-002448-10 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
American Medical Association FoundationWithdrawnIdiopathic Pulmonary Arterial Hypertension.United States
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Scleroderma Associated Pulmonary Arterial Hypertension | Appetite Suppressant Associate PAHUnited States
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaboratorsUnknownPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Deep Phenotyping | Heritable Pulmonary Arterial HypertensionKorea, Republic of
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisUnknownPulmonary Arterial Hypertension (PAH)France
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchCompletedIdiopathic Pulmonary Arterial HypertensionAustria
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Regina Steringer-MascherbauerUnknownPulmonary Arterial Hypertension WHO Group IAustria
Clinical Trials on Zamicastat
-
Bial - Portela C S.A.CompletedPulmonary Arterial HypertensionAustria, Germany, Italy, Portugal, Spain, United Kingdom
-
Bial - Portela C S.A.TerminatedPulmonary Arterial Hypertension
-
Bial - Portela C S.A.CompletedPulmonary Arterial HypertensionNetherlands
-
Bial - Portela C S.A.CompletedHypertension and Chronic Heart FailureNetherlands
-
Bial - Portela C S.A.CompletedPulmonary Arterial Hypertension | Cardiovascular Disease+Pulmonary DiseaseUnited Kingdom
-
Bial - Portela C S.A.Completed
-
Bial - Portela C S.A.CompletedPulmonary Arterial HypertensionGermany
-
Bial - Portela C S.A.CompletedPulmonary Arterial HypertensionGermany
-
Bial - Portela C S.A.CompletedPulmonary Arterial HypertensionGermany